Recursion Pharmaceuticals (NASDAQ:RXRX) used its latest earnings call to emphasize what management described as an inflection ...

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...

Abstract: Efficient rigid-body dynamics algorithms are instrumental in enabling high-frequency dynamics evaluation for resource-intensive applications (e.g., model predictive control, large-scale ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...

Submodular maximization is a significant area of interest in combinatorial optimization, with numerous real-world applications. A research team led by Xiaoming SUN from the State Key Lab of Processors ...

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...

We often think about the impact AI is making on profitable businesses and even governmental organizations, but AI is also making significant contributions to the operations and success of non-profit ...

MicroAlgo Inc. announced its research on the Quantum Information Recursive Optimization (QIRO) algorithm, which aims to address complex combinatorial optimization problems using quantum computing.

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...